BX-795   Click here for help

GtoPdb Ligand ID: 8006

Synonyms: BX 795 | BX795
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: BX-795 is a potent, ATP-competitive inhibitor of 3-phosphoinositide dependent protein kinase 1 (PDK1). The discovery of BX-795 is described in [3] and is claimed in patent WO2004048343 [1]. The PDK1/Akt signaling pathway plays a key role in cancer cell growth, survival, and tumour angiogenesis and represents a promising target for oncology therapeutics. BX-795 has subsequently been discovered to inhibit other kinases, such as TANK-binding kinase 1 (TBK1) and IkappaB kinase epsilon (IKKε) [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 4
Rotatable bonds 12
Topological polar surface area 139.52
Molecular weight 591.09
XLogP 3.29
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(N1CCCC1)Nc1cccc(c1)Nc1ncc(c(n1)NCCCNC(=O)c1cccs1)I
Isomeric SMILES O=C(N1CCCC1)Nc1cccc(c1)Nc1ncc(c(n1)NCCCNC(=O)c1cccs1)I
InChI InChI=1S/C23H26IN7O2S/c24-18-15-27-22(30-20(18)25-9-5-10-26-21(32)19-8-4-13-34-19)28-16-6-3-7-17(14-16)29-23(33)31-11-1-2-12-31/h3-4,6-8,13-15H,1-2,5,9-12H2,(H,26,32)(H,29,33)(H2,25,27,28,30)
1. Arnaiz D, Boemer U, Briem H, Bryant J, Buckman B, Eckle E, Esperling P, Feldman R, Huwe P, Khim S-K et al.. (2004)
Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents.
Patent number: WO2004048343. Assignee: Schering Ag. Priority date: 28/11/2002. Publication date: 10/06/2004.
2. Clark K, Plater L, Peggie M, Cohen P. (2009)
Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation.
J Biol Chem, 284 (21): 14136-46. [PMID:19307177]
3. Feldman RI, Wu JM, Polokoff MA, Kochanny MJ, Dinter H, Zhu D, Biroc SL, Alicke B, Bryant J, Yuan S et al.. (2005)
Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.
J Biol Chem, 280 (20): 19867-74. [PMID:15772071]
4. Hasan M, Yan N. (2016)
Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies.
Pharmacol Res, 111: 336-42. [PMID:27353409]